ARCHIVES

ODAC Advice Poses Challenge to FDA: Would Iressa Approval Erode Standards?

This article is from The Cancer Letter archive.

Vol. 28 No. 41 | November 8, 2002

Download PDF Visit The Full Archive

Related Articles

NSABP Investigator Recounts Loyalty To Fisher, “Betrayal”

June 3, 1994

NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.

July 13, 2007

NCCN Launches Outcomes Improvement Program

August 12, 2011

Afinitor Suspension Approved For Rare Pediatric Brain Tumor

August 31, 2012

NCI Will Encourage More Activity In Environment Carcinogenesis

June 21, 1974

By Defending Potti, Duke Officials Become Target Of Charges Of Institutional Failure

July 23, 2010